WHO ICTRP trial
Comparison of Berizym and Pancrelipase for the effect to suppress onset of…
JPRN-UMIN000022536 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000022536 |
|---|---|
| Public title | Comparison of Berizym and Pancrelipase for the effect to suppress onset of Hepatic Steatosis after Pancreaticoduodenectomy |
| Scientific title | Comparison of Berizym and Pancrelipase for the effect to suppress onset of Hepatic Steatosis after Pancreaticoduodenectomy - ESOP Trial |
| Primary sponsor | National Cancer Center Hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not applicable |
| Countries | Japan |
| Conditions | Patients who underwent pancreaticoduodenectomy |
| Interventions | Administration of Berizym. Patients assigned to the standard treatment group start taking Berizym, which is conventional compound of digestive enzymes within 3 days after registration. Daily amount of 3 g of Berizym is taken during or after… |
| Registration date | May 31, 2016 |
| Target size | 300 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: